A NOVEL COMBINATION TO DEFEAT LIFE THREATENING ORGANISM PSEUDOMONAS AERUGINOSA

Abstract

There is global increase in resistance among bacterial species that lead to critical infections. Most of the Gram-negative bacteria are labelled as multi drug resistant. Among all different species, the Pseudomonas aeruginosa (P.aeruginosa) is one of the leading causes of life-threatening infections. It has become difficult to treat P.aeruginosa infections in current scenario as antimicrobial resistance has increased against antimicrobial drugs. So it has become a challenge to select optimal antibacterial drug or regimen for the patient treatment to prevent further resistance.
Ceftolozane/tazobactam (C/T) is a novel combination of broad spectrum antibacterial agents that is 5th generation cephalosporin antibiotic and β-lactamase inhibitor. It is considered a best choice for the treatment of complicated infections including ventilator-associated bacterial pneumonia, nosocomial pneumonia, urinary tract infections and intra-abdominal infections.
Ceftolozane/tazobactam possess sensitivity of about >90% against β-lactam resistant strains of P.aeruginosa. This combination is superior to various other antibiotics and antibacterial regimen so it has initiated a new chapter in an era of complicated infections.
This review appraises the comparison of different broad spectrum antibiotics like levofloxacin, meropenem and tobramycin and antibacterial combinations including tazobactam/cefepime, ceftazidime/avibactam, tazobactam/piperacillin, with the Ceftolozane/tazobactam combination. This article also evaluates the effect of C/T if given in combination with other drugs like daptomycin, metronidazole and amikacin.